Project Grant R21AI186331
Award Date
6/24/24
Completion Date
4/30/26
Dollars Obligated
$934K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
This federal Project Grant award, identified as R21AI182639, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $205,125 grant was awarded to the Hennepin Healthcare Research Institute (HHRI) to investigate the use of a Plasmodium vaccine and the impact of microbial exposure on vaccine efficacy in a mouse model. The key objectives are to: 1) define the T cell and antibody response to...
This federal Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the molecular mechanisms of malaria parasite-mosquito midgut interactions and develop new transmission-blocking approaches. The key objectives are to functionally characterize mosquito and parasite proteins that mediate these interactions, evaluate their potential as...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,160 Project Grant (CFDA 93.855 Allergy and Infectious Diseases Research) to George Washington University to develop mRNA-LNP vaccines targeting multiple stages and species of the human malaria parasite. The research aims to evaluate protective efficacy of vaccine antigens individually and in combination for both Plasmodium falciparum and Plasmodium vivax malaria, with studies planned in mice and non-human...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $924,000 in funding to Tufts University School of Medicine. The award aims to support research focused on mitigating the adhesion of Plasmodium falciparum-infected red blood cells to endothelial cells, a key factor in the development of severe and often fatal cerebral malaria. The research project will...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $2,960,775.00 in funding to the University of Iowa to conduct research on mechanisms underlying reduced efficacy of malaria vaccines in individuals with prior malaria exposure. The key objectives are to: 1) Determine how the malaria byproduct hemozoin disrupts antigen presentation and CD8 T cell priming after vaccination...
This $676,425 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the mechanisms by which the Plasmodium falciparum parasite causes neutrophil dysfunction during malaria infection. The research team at The Washington University aims to identify how the parasite's secreted histidine-rich protein II (HRPII) impairs the oxidative burst activity of neutrophils, a...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover targets of naturally acquired immunity against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The $708,202 grant, awarded to Brown University on December 20, 2024, will support a case-control study in a malaria-endemic region of western Kenya to identify...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $479,204 Project Grant (CFDA 93.855) to the University of Maryland, Baltimore to conduct research on parasite variant surface antigens and their role in severe malaria. The 2-year project, titled "Parasite Variant Surface Antigen Expression and Immune Gaps in Severe Malaria," aims to identify parasite genes associated with severe malaria in order to inform the development of vaccines or therapeutics. The...
This $707,696 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to identify volatile organic compounds in human scent signatures that modulate attractiveness to the African malaria mosquito Anopheles gambiae, a primary vector for malaria transmission in sub-Saharan Africa. The research aims to characterize the contribution of the human skin microbiome to these scent signatures...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a five-year, $690,500 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Trustees of Boston University Medical Campus to investigate the immune mechanisms underlying the poor responsiveness to the booster dose of the RTS,S malaria vaccine in African children. The research project will follow a cohort of 600 Malawian children to comprehensively analyze antibody responses, innate cell functions, T cell...